Soleno Therapeutics, Inc. announced that data from the randomized withdrawal period of Study C602 of DCCR extended-release tablets in Prader-Willi Syndrome will be featured in an oral presentation.
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Aardvark Therapeutics secures $85m in Series C funding round pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
REDWOOD CITY, Calif., April 30, 2024 Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the.